The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.
 
Maria M Zlobinsky Rubinstein
No Relationships to Disclose
 
Robert James Gray
Research Funding - Abbott Molecular; Agios; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Genomic Health; Genzyme; GlaxoSmithKline; ImClone Systems; Janssen-Ortho; Kanisa; Millennium; Nodality; Onyx; OSI Pharmaceuticals; Pfizer; Sanofi; Sequenta; Syndax
 
Joseph A. Sparano
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Curis; Curis; Eisai; Genentech/Roche; Johnson & Johnson; Novartis; Sanofi
Research Funding - Merck (Inst)
 
JoAnne Zujewski
No Relationships to Disclose
 
Timothy Joseph Whelan
No Relationships to Disclose
 
Kathy S. Albain
Honoraria - Genomic Health
Consulting or Advisory Role - bioTheranostics; Genentech; Genomic Health; NanoString Technologies; Novartis
Travel, Accommodations, Expenses - Genentech; Genomic Health
Other Relationship - Pfizer
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion; OncImmune
Honoraria - 3rd UK Breast Cancer Meeting, Londong; Lilly
Consulting or Advisory Role - Pfizer
Research Funding - AstraZeneca (Inst); Janssen Research & Development (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.; Title: Circulating tumor cell capturing techniques and devices. Original application no. 61/593,092.; Title: Diagnosis and treatment of breast cancer. Original application no. 61/079,642; Revised application no. 61/224,310.
 
Charles E. Geyer
Travel, Accommodations, Expenses - AstraZeneca
 
Elizabeth Claire Dees
Consulting or Advisory Role - Amgen (I); Novartis (I)
Research Funding - Agensys; Bayer; Genentech/Roche; Lilly/ImClone; Millennium; Novartis; Pfizer
 
Edith A. Perez
No Relationships to Disclose
 
Maccon M. Keane
No Relationships to Disclose
 
Carlos Vallejos
No Relationships to Disclose
 
Timothy F. Goggins
No Relationships to Disclose
 
Ingrid A. Mayer
Consulting or Advisory Role - Genentech/Roche; Novartis
Research Funding - Novartis
 
Adam Brufsky
Honoraria - Genentech/Roche
Consulting or Advisory Role - Agendia; bioTheranostics; Celgene; Genentech/Roche; Genomic Health; Novartis
 
Deborah Toppmeyer
Employment - Novartis (I)
Stock and Other Ownership Interests - Novartis (I)
Travel, Accommodations, Expenses - Novartis
 
Virginia G. Kaklamani
Speakers' Bureau - Genomic Health
 
James Norman Atkins
No Relationships to Disclose
 
Jeffrey L. Berenberg
No Relationships to Disclose
 
George W. Sledge
Leadership - Syndax
Stock and Other Ownership Interests - Syndax
Honoraria - Genentech; Symphony Evolution
Consulting or Advisory Role - Symphony Evolution
Research Funding - Genentech/Roche (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline